Format

Send to

Choose Destination
J Clin Pharmacol. 2015 Mar;55(3):258-60. doi: 10.1002/jcph.425. Epub 2014 Dec 30.

Genes affecting warfarin response-interactive or additive?

Author information

1
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida at Gainesville, Gainesville, FL, USA.
2
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.

Abstract

Genotypes for cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) contribute significantly to the inter-patient variability in warfarin dose requirements. These genotypes in addition to clinical factors explain approximately 50% of the dose variability in Europeans, but less in other populations. Thus, a large portion of the variability remains unexplained and has been the focus of on-going research. Trials evaluating the clinical utility of genotype-guided warfarin dosing have shown a benefit in Europeans, but not in an ethnically diverse cohort. Identifying and accounting for variants important in non-European populations will likely be necessary before a benefit with genotype-guided dosing will be realized in these populations.

KEYWORDS:

CYP2C9; VKORC1; genotype; warfarin

PMID:
25385663
PMCID:
PMC5639939
DOI:
10.1002/jcph.425
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center